Despite significant progress, there remains a risk of a mad rush to compliance in late 2023 with pending requirements for ensuring the legitimacy of drug products in the US distribution chain, the Healthcare Distribution Alliance has found.
Meeting 10-Year DSCSA Serialization Mandate Requires Industry Big Push In Final Year
HDA finds much progress to report in seventh annual Serialization Readiness Survey, but quite a lot of work remains for many drug manufacturers and distributors if they are to meet November 2023 compliance deadline.
More from Manufacturing
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.